Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Triesence Generic Name & Formulations
Legal Class
Rx
General Description
Triamcinolone acetonide 40mg/mL; susp for intravitreal inj.
Pharmacological Class
Glucocorticoid.
How Supplied
Single-use vial (1mL)—1
Manufacturer
Mechanism of Action
Naturally occurring glucocorticoids, which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs such as prednisolone and triamcinolone are primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone acetonide possesses glucocorticoid activity typical of this class of drug, but with little or no mineralocorticoid activity.
Triesence Indications
Indications
Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Visualization during vitrectomy.
Triesence Dosage and Administration
Adults and Children
Give anesthesia and broad-spectrum microbicide prior to use. Ophthalmic diseases: initially 4mg (100microliters); may repeat if needed. Visualization: 1–4mg (25–100microliters) intravitreally.
Triesence Contraindications
Contraindications
Systemic fungal infections. Live vaccination.
Triesence Boxed Warnings
Not Applicable
Triesence Warnings/Precautions
Warnings/Precautions
Not for IV administration. Ocular herpes simplex. Cerebral malaria: not recommended. Tuberculosis. If exposed to chickenpox or measles, consider prophylactic passive immune therapy. Strongyloides infestation. Latent amebiasis. Thyroid disorders. Diabetes. CHF. Hypertension. Recent MI. Renal insufficiency. GI perforation. Diverticulitis. Intestinal anastomoses. Peptic ulcer. Myasthenia gravis. Hypoprothrombinemia. Monitor for osteoporosis (esp. postmenopausal women) if on long-term therapy; do bone density tests. Supplement with additional steroids in physiologic stress. Monitor growth, weight, blood pressure, fluid and electrolyte balance. Avoid abrupt cessation. Pregnancy (Cat.D); (avoid in 1st trimester). Nursing mothers.
Triesence Pharmacokinetics
Elimination
Renal. Half-life: ~18.7 days.
Triesence Interactions
Interactions
Potentiated by CYP3A4 inhibitors (eg, ketoconazole, macrolides), cyclosporine, estrogens. Antagonized by CYP3A4 inducers (eg, barbiturates, phenytoin, carbamazepine, rifampin), ephedrine, cholestyramine. May potentiate cyclosporine. May antagonize anticoagulants (monitor), isoniazid. Increased risk of arrhythmias with digitalis. May need to adjust dose of antidiabetic agents. Increased GI effects with aspirin, other NSAIDs. Monitor for hypokalemia with potassium-depleting drugs (eg, amphotericin B, diuretics). Withdraw anticholinesterase agents at least 24 hours before starting corticosteroid therapy. May suppress reactions to skin tests.
Triesence Adverse Reactions
Adverse Reactions
Elevated intraocular pressure (monitor), cataracts, endophthalmitis, hypopyon, inj site reactions, glaucoma, vitreous floaters, retinal pigment epithelium detachment, optic disc vascular disorder, eye inflammation, conjunctival hemorrhage, reduced visual acuity, HPA axis suppression, masks infection, increased susceptibility to infection, hypertension, hypokalemia, weight gain, osteoporosis, behavioral or mood disturbances, myopathy, Kaposi's sarcoma.
Triesence Clinical Trials
See Literature
Triesence Note
Not Applicable
Triesence Patient Counseling
See Literature
